 |
5 Diseases |  |
0 Trials |
|
0 Trials |  |
5 News |  |
- || NTM-006 / Neumentum
Review, Journal: Exploring acetaminophen prodrugs and hybrids: a review. (Pubmed Central) - Mar 25, 2024
Prime examples of APAP-based drugs such as propacetamol, benorylate, acetaminosalol, nitroparacetamol, and agent JNJ-10450232 weave well into this classification. The proposed classification is the first and original, giving a better understanding of the SAR studies for new pain relievers research and the design development for the analgesic APAP-(or NSAID)-based compounds.
- | NTM-006 / Neumentum
Preclinical, Journal: Preclinical safety assessment of JNJ-10450232 (NTM-006), a structural analog of acetaminophen, that does not cause hepatotoxicity at supratherapeutic doses. (Pubmed Central) - Jan 8, 2023
JNJ-10450232 (NTM-006) had no toxicologically relevant findings in safety pharmacology or genotoxicity studies. Together, these data supported progressing into safety and efficacy studies in humans.
- NTM-006 / Neumentum
Update on NTM-006, a Novel Orally-Active Non-Opioid Analgesic: Molecular-Modeling Consistent with Allosteric Modulation of the Adenosine A3 Receptor () - Sep 19, 2022 - Abstract #PAINWeek2022PAINWeek_219;
The results of the molecular modeling reported here supports this hypothesis. The combination of binding processes would be consistent with NTM-006's in vitro , animal model, and clinical characteristics of broad-spectrum and pronounced analgesic efficacy, and long-duration of analgesic action.
- || paracetamol / Generic mfg.
P1 data, PK/PD data, Journal: First-in-human study to evaluate the safety, tolerability and pharmacokinetics of a novel analgesic and antipyretic drug with structural similarity to acetaminophen. (Pubmed Central) - Sep 10, 2022
Transient increases in indirect bilirubin were noted at post-baseline timepoints due to UGT1A1 inhibition, without any evidence of adverse hepatic effects. Macular rash and generalized erythema were the most common drug-related adverse events after multiple doses.
- NTM-006 / Neumentum
Update on In Vivo Testing of NTM-006 (formerly JNJ-10450232), a Novel Orally-Active Non-Opioid Analgesic: Neuropathic Pain Model () - Sep 15, 2021 - Abstract #PAINWeek2021PAINWeek_100;
It was recently found to have efficacy in the Complete Freund’s adjuvant and carrageenan paw models of inflammatory pain (see companion poster). Based on in vitro assays, NTM-006 appears to exert its primary action at adenosine A3 receptor sites, a mechanism that is suggestive of possible efficacy against neuropathic pain.
- NTM-006 / Neumentum
Update on In Vivo Testing of NTM-006 (formerly JNJ-10450232), a Novel Orally-Active Non-Opioid Analgesic: CFA and Paw Edema () - Sep 15, 2021 - Abstract #PAINWeek2021PAINWeek_99;
Based on in vitro assay screens, the compound is non-opioid, and non-NSAID (does not inhibit COX-1 or COX-2 cyclooxygenase isozymes) at doses that produce its antinociceptive and antipyretic effects. Based on in vitro assays, NTM-006 appears to exert its primary action at adenosine A3 receptor sites, possibly as an allosteric modulator (A3RM).
- |||| NTM-006 / Neumentum
Trial completion: A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine (clinicaltrials.gov) - May 5, 2015
P2, N=269, Completed, Sponsor: McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Based on in vitro assays, NTM-006 appears to exert its primary action at adenosine A3 receptor sites, possibly as an allosteric modulator (A3RM). Recruiting --> Completed
- |||| NTM-006 / Neumentum
Enrollment open: A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine (clinicaltrials.gov) - Aug 15, 2014
P2, N=264, Recruiting, Sponsor: McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| NTM-006 / Neumentum
New P2 trial: A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine (clinicaltrials.gov) - Aug 5, 2014
P2, N=264, Not yet recruiting, Sponsor: McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.